Akihiro Takeshita

Hamamatsu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Adverse events during preoperative autologous blood donation and its usage in obstetrical patients: A multicenter, retrospective survey in Japan.

Adverse events during preoperative autologous blood donation and its usage in obstetrical patients: A multicenter, retrospective survey in Japan.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: November 05, 2024

Allo-anti-M: Detection peaks around 2 years of age, but may be attenuated by red blood cell transfusion.

Allo-anti-M: Detection peaks around 2 years of age, but may be attenuated by red blood cell transfusion.

Journal: Transfusion

Published: February 12, 2021

Erythrocyte Alloimmunity and Genetic Variance: Results from the Collaborative Study of Alloimmunity to Antigen Diversity in Asian Populations (All ADP).

Erythrocyte Alloimmunity and Genetic Variance: Results from the Collaborative Study of Alloimmunity to Antigen Diversity in Asian Populations (All ADP).

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: November 24, 2020

A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.

A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.

Journal: Vox sanguinis

Published: September 03, 2020

Transfusion-associated circulatory overload and high blood pressure: A multicentre retrospective study in Japan.

Transfusion-associated circulatory overload and high blood pressure: A multicentre retrospective study in Japan.

Journal: Vox sanguinis

Published: May 04, 2020

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.

Journal: Cancers

Published: May 03, 2020

Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan.

Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan.

Journal: International journal of hematology

Published: April 07, 2020

Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.

Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.

Journal: Annals of hematology

Published: December 24, 2019

Clinical significance of autologous blood transfusions in bone marrow harvest from unrelated donors.

Clinical significance of autologous blood transfusions in bone marrow harvest from unrelated donors.

Journal: International journal of hematology

Published: December 22, 2019

A Japanese multi-institutional collaborative study of antigen-positive red blood cell (RBC) transfusions in patients with corresponding RBC antibodies.

A Japanese multi-institutional collaborative study of antigen-positive red blood cell (RBC) transfusions in patients with corresponding RBC antibodies.

Journal: Vox sanguinis

Published: August 14, 2019

Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.

Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.

Journal: International journal of hematology

Published: December 11, 2018

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Journal: British journal of haematology

Published: November 24, 2018

Showing 1-12 of 32

Last Updated: 09/26/2026